Contact this trialFirst, we need to learn more about you.
Hormone Therapy
Fulvestrant +2 More for Breast Cancer
Recruiting3 awardsPhase < 1
Pittsburgh, Pennsylvania
This study is evaluating whether there are differences in the frequency of ESR1 mutations in plasma between patients treated with Fulvestrant plus palbociclib and patients treated with Tamoxifen plus palbociclib.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.